For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and the formulated version represents a genuine change. These novel therapies protect the transthyretin protein, halting its destructive build-up and alleviating the severity of the condition . Individuals are now seeing posi… Read More